Reviews Ticlopidine Hcl


No reviews yet.

Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008




Ticlid Drug Description
TICLID®
(ticlopidine hydrochloride) Tablets

WARNING
TICLID can cause life-threatening hematological adverse reactions, including
neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia.
Neutropenia/Agranulocytosis: Among 2048 patients in clinical
trials in stroke patients, there were 50 cases (2.4%) of neutropenia (less than
1200 neutrophils/mm³), and the neutrophil count was below 450/mm³
in 17 of these patients (0.8% of the total population).
TTP: One case of thrombotic thrombocytopenic purpura was reported
during clinical trials in stroke patients. Based on postmarketing data, US physicians
reported about 100 cases between 1992 and 1997. Based on an estimated patient
exposure of 2 million to 4 million, and assuming an event reporting rate of
10% (the true rate is not known), the incidence of ticlopidine-associated TTP
may be as high as one case in every 2000 to 4000 patients exposed.
Aplastic Anemia: Aplastic anemia was not seen during clinical
trials in stroke patients, but US physicians reported about 50 cases between
1992 and 1998. Based on an estimated patient exposure of 2 million to 4 million,
and assuming an event reporting rate of 10% (the true rate is not known), the
incidence of ticlopidine-associated aplastic anemia may be as high as one case
in every 4000 to 8000 patients exposed.
Monitoring of Clinical and Hematologic Status: Severe hematological
adverse reactions may occur within a few days of the start of therapy. The incidence
of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately
4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks
of therapy. The incidence of the hematologic adverse reactions declines thereafter.
Only a few cases of neutropenia, TTP, or aplastic anemia have arisen after more
than 3 months of therapy.
Hematological adverse reactions cannot be reliably predicted by any identified
demographic or clinical characteristics. During the first 3 months of treatment,
patients receiving TICLID must, therefore, be hematologically and clinically
monitored for evidence of neutropenia or TTP. If any such evidence is seen,
TICLID should be immediately discontinued.
The detection and treatment of ticlopidine-associated hematological adverse
reactions are further described under WARNINGS.

DRUG DESCRIPTION



What are the possible side effects of ticlopidine (Ticlid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using ticlopidine and call your doctor at once if you have a serious side effect such as:

nosebleed or other bleeding that will not stop;
black, bloody, or tarry stools;
coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy feeling, pain spreading to the arm or shoulder,...
Read All Potential Side Effects for Ticlid »




TICLID (ticlopidine hydrochloride) is a platelet aggregation inhibitor. Chemically
it is 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride.
The structural formula is:








Ticlopidine hydrochloride is a white crystalline solid. It is freely soluble
in water and self-buffers to a pH of 3.6. It also dissolves freely in methanol,
is sparingly soluble in methylene chloride and ethanol, slightly soluble in
acetone and insoluble in a buffer solution of pH 6.3. It has a molecular weight
of 300.25.
TICLID tablets for oral administration are provided as white, oval, film-coated,
blue-imprinted tablets containing 250 mg of ticlopidine hydrochloride. Each
tablet also contains citric acid, magnesium stearate, microcrystalline cellulose,
povidone, starch and stearic acid as inactive ingredients. The white film-coating
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide.
Each tablet is printed with blue ink, which includes FD&C Blue #1 aluminum
lake as the colorant. The tablets are identified with Ticlid on one side and
250 on the reverse side.Last reviewed on RxList: 6/10/2008





Other reviews about Ticlopidine Hcl on wordpress

Sanofi-Aventis - Business & Products
  by El Horror
About - 2004: Sanofi-Synthélabo acquires Aventis by friendly bid of €54.5 bn. - Merial = Merger of Merck & Co. Inc. and Sanofi-Aventis in 1997. Merck sells its 50% to […]


Pain Killers Free online pharmacy courses
  by jamarionepuckette
LAUNDRY RENOVATION IDEAS This too helps prozac nation reviews to make your immune system stronger pain management as well, and this is just another of the many […]


The dogs and sledge are m
  by ijxfrmflgfg
Also they had another reason for wanting to catch the fish they feared that in some way the three Adepts might regain their proper forms and then they […]


As Bender and the assistant wa
  by gogbfywfxxkj
The Collector will be here and be pained. Didnt matter, whatever they were. The tall captain took the keys and led the way to our cabin. He was […]


The region into which we drove was utte
  by xidfwxwvboupfe
Morel was leaning against the counter, ashamed, halfgrinning. Griffiths yelled in the mates ear, at the same time studying the ketchs behaviour. Doc Strowbridge told me about […]


Under the second head, periodical dema
  by tgikcbfobt
She little fall, went on Mukoki, brightening as the odor of coffee and meat filled his nostrils. Next morning the priest was in a very bad temper, […]


In his stupid Teutonic way he tried
  by cfghboltsxwyxm
He never could consent to any such scheme. The gurgle and slurp and chuckle of rain in gutters and downspouts. I give him my business card with the […]


Wet and rotten leaves reeked and fes
  by bvctskoowjpx
Lately I havent been hungry for meat, so I suppose I dont need any. Viaburi I You stop along kitchen. Muribellum was a head taller than the tallest […]


Within the sand castle dwells an ogre
  by cvzxyqypacfw
It had been pointed out to this general that no acts of sabotage had occurred on the West Coast, where the naturalized Japanese were most heavily concentrated. There […]


The favored portions of the ear
  by bzwnapnfawqabct
But, Faith, you might really die. ask for him the kingdom also; for he is mine elder brother; even for him, and for Abiathar the priest, and for […]



Other reviews about Ticlopidine Hcl on web:

Learn about the prescription medication Ticlid (Ticlopidine Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ticlid (Ticlopidine Hcl) Drug Information: Uses, Side Effects ...


Ticlopidine HCl is a platelet aggregation inhibitor used to reduce the risk of stroke. Side effects and interactions are available at drugstore.com; plus get home delivery from a ... Ticlopidine Hcl - drugstore.com. Low prices, side effects ...


TICLOPIDINE HYDROCHLORIDE - ticlopidine hydrochloride tablet, film coated Apotex Corp.-----TICLOPIDINE HCl TABLETS 250 mg TICLOPIDINE HCl TABLETS 250 mg


Important Note: The Following Information Is Intended To Supplement, Not Substitute For, The Expertise And Judgment Of Your Physician, Pharmacist Or Other Healthcare Professional. TICLOPIDINE HCL Patient Assistance Program


Ticlid™ [Ticlopidine HCL] Description / Properties Ticlopidine is an inhibitor of platelet aggregation. It causes dose-dependent inhibition of platelet aggregation and release of ... SEARLE Pakistan Ltd. | Products | Ticlid ™


Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they ...


Information on ticlopidine (Ticlid) a drug prescribed for the prevention of strokes or TIAs (mini-strokes) to prevent blood clots in stents placed in the heart. Off label uses are ... Ticlopidine (Ticlid) Drug Information by MedicineNet.com


Ticlopidine belongs to the class of medications called antiplatelets . It works by preventing ... ticlopidine HCl By Roche Ticlid - Uses, Side effects, Interactions, Warnings, Indications ...


Threlkeld DS, ed. Blood Modifiers, Antiplatelet Agents, Ticlopidine HCl. In Facts and Comparisons Drug Information. St. Louis, MO: Facts and Comparisons, Jan 1992, 85c–5g. mothernature.com - ticlopidine


TICLID® Roche Ticlopidine HCl Inhibitor of Platelet Function Action and Clinical Ticlopidine is an inhibitor of platelet aggregation. It causes a time and dose-dependent ... RxMed: Pharmaceutical Information - TICLID





Featured Reviews

Reviews Flonase

Flonase Drug Description FLONASE® (fluticasone propionate) Nasal Spray, 50 mcg SHAKE GENTLY BEFORE USE. For Intranasal Use Only. DRUG DESCRIPTION What are the possible side effects of fluticasone nasal (Flonase, Veramyst)? Get...
Read More  |  Review This
Reviews Ascorbic Acid

Ascorbic Acid Drug Description Ascorbic Acid Injection, USP No preservative added. DRUG DESCRIPTION Ascorbic acid (vitamin C) is a water-soluble vitamin. It occurs as a white or slightly yellow crystal or powder with a slight acidic taste....
Read More  |  Review This
Reviews Cefadroxil

Cefadroxil Drug Description Cefadroxil (cefadroxil hemihydrate) Tablet, Film Coated Cefadroxil (cefadroxil hemihydrate) Capsule To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefadroxil...
Read More  |  Review This
Reviews Mycophenolic Acid

Myfortic Drug Description Myfortic® (mycophenolic acid*) Delayed-Release Tablets *as Mycophenolate Sodium WARNING Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma and...
Read More  |  Review This
Reviews Mumpsvax

Mumpsvax Drug Description MUMPSVAX® (Mumps Virus Vaccine Live) Jeryl Lynn™ Strain DRUG DESCRIPTION What are the possible side effects of this vaccine (Mumpsvax)? Keep track of any and all side effects your child has after...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....